<DOC>
	<DOCNO>NCT01736891</DOCNO>
	<brief_summary>The objective study evaluate efficacy , tolerability , safety rasagiline compare placebo PD patient motor fluctuation levodopa therapy .</brief_summary>
	<brief_title>Clinical Trial Rasagiline Levodopa-Treated Parkinson 's Disease Patients With Motor Fluctuations</brief_title>
	<detailed_description>Levodopa mainstay therapy PD decade , consider one effective medication relief symptom PD . However , within month year majority levodopa-treated patient notice decline duration benefit dose develop motor-complications . A major problem appearance fluctuation mobility , cycle ON OFF period . The administration rasagiline , MAO-B inhibitor , slow elimination endogenous dopamine supply dopamine produce exogenous levodopa therapy may therefore improve ON-OFF fluctuation . The objective study evaluate efficacy , tolerability , safety rasagiline compare placebo PD patient motor fluctuation levodopa therapy .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Patients idiopathic PD Patients receive least 300 mg daily dos levodopa less 8 daily dos levodopa stable dose Patient Modified Hoehn Yahr stage 2 4 OFF state Patient motor fluctuation average least 2 hour daily OFF state Patients demonstrate ability keep accurate 24hour diary Patients Parkinsonian syndrome induce medicine , metabolic disease , Encephalitis central nervous system degenerative disease Disease basal ganglion Patients severe cognitive impairment judge Mini Mental State Examination Patients clinically significant psychiatric illness Patients Hamilton Depression Rating Scale ( HAMD ) : total score ≤10 Patients clinically significant unstable medical surgical condition would preclude safe complete study participation Patients clinically significant unstable vascular disease Patients severe disable dyskinesia Other inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Motor fluctuation</keyword>
	<keyword>Parkinson´s Disease</keyword>
	<keyword>Rasagiline</keyword>
</DOC>